Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Quest Diagnostics to offer US FDA-approved Fujirebio blood test for Alzheimer's disease: Secaucus, New Jersey Friday, July 11, 2025, 14:00 Hrs [IST] Quest Diagnostics, a leader in ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

About Fujirebio Fujirebio is global R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value.

Business Wire India H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of ...

MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of ...

Ixico said it was contracted by Fujirebio Diagnostics Inc, a Tokyo-based biomarker research company, to assist with the development of a new blood-based test for Alzheimer's disease called Lumipulse.

The Food and Drug Administration (FDA) cleared the first blood test recently to help diagnose Alzheimer's disease. The test, manufactured by Fujirebio Diagnostics, is for those aged 55 and older ...